Search
Learn about some of the most important advances in cancer treatment and clinical trials at MSK in 2024.
Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism that tumors themselves use to metastasize throughout the body. This work, which will be featured on the cover of the June 29 issue of Science Translational Medicine, was applicable across a wide range of tumor and drug types and can potentially be applied to other conditions including vascular and autoimmune diseases.
A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable.
The U.S. Food and Drug Administration (FDA) approved 11 cancer drugs in 2024 based on significant contributions from MSK researchers.
Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.
Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.
Meet Andrew Kung, MSK’s new Chair of the Department of Pediatrics.
Obtenga información sobre el programa de observación activa de MSK para el cáncer de tiroides papilar, que permite a muchas personas evitar cirugías innecesarias y los riesgos que estas tienen.
Though questions remain about how best to use genetic testing for cancer, the trend is toward more inclusive criteria.
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.